Reunion Neuroscience — Reunion Neuroscience announced peer-reviewed publication of Phase 1 data for RE104, its subcutaneous, shorter-duration serotonergic psychedelic prodrug.
The publication supported RE104's pharmacology and tolerability profile ahead of its Phase 2 RECONNECT study in postpartum depression. For the private developer, the journal placement adds scientific credibility to a differentiated, shorter-acting candidate.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.